| Project/Area Number |
20F20112
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 外国 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
落谷 孝広 東京医科大学, 医学部, 教授 (60192530)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
PRIETO-VILA MARTA 東京医科大学, 医学部, 外国人特別研究員
|
|---|
| Project Period (FY) |
2020-04-24 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 2021: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2020: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | Single-cell analysis / Breast cancer / Metastasis / Single-cell RNA seq / Genetic profile / Cancer / RNA single-cell sequence / breast cancer / metastasis |
|---|
| Outline of Research at the Start |
乳がんの臨床検体を用いた単一細胞レベルで発現解析をすることで転移性および抗がん剤耐性能を持つ乳がん幹細胞の特性を明らかにすること、さらに腫瘍内に混在する亜集団を明らかにすることを目的とする。がん細胞のみに焦点をあてるだけでなく、がん細胞を含んだがん微小環境の包括的な解明を試みる。具体的には以下２点である。乳がんの臨床検体で単一細胞RNA-seqを使用して、転移および薬物耐性能に関与する遺伝子群を明らかにする。そして、原発巣と転移巣のがん微小環境を単一細胞レベルで解析することで、腫瘍の転移に有利に働く非がん細胞とがん細胞の相互作用について理解する。
|
| Outline of Annual Research Achievements |
Through this collaborative research, we have obtained convincing data to say that primary Breast cancer tumors already have a small subpopulation of cells with metastatic characteristics. Results obtained by Dr. Prieto-Vila during the two years of her JSPS fellowship not only have importance in basic breast cancer research but also bear significance in treatments. Identifying metastatic cells at the early stages of cancer will be significant for the accurate treatment of the patients and an improvement in their survival.
Due to the covid-19 situation, the initial steps of this research were delayed. We could not obtain clinical samples for a long time and Dr. Prieto-Vila wrote a review article at that time. For these reasons along with small complications in the single-cell analyses, the current work has not finished yet. Dr. Prieto-Vila had been working for us in the past and I hired her from now on as well, so we plan to complete this work within this fiscal year.
The results so far were presented at several conferences including the 80th Annual Japanese association of Cancer as a poster presentation, and this year, in 2022 it was submitted as an oral presentation. In concrete, in one of those conferences, she met researchers from a research group in Valencia, Spain with whom we kept in contact and recently wrote an international collective collaboration.
In summary, the collaborative research has been very successful with three published papers as a first author, and some other manuscripts under submission.
|
| Research Progress Status |
令和3年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
令和3年度が最終年度であるため、記入しない。
|
